B cell receptor signatures associated with strong and poor SARS-CoV-2 vaccine responses. Issue 1 (31st December 2022)

• Record Type: Journal Article
• Authors: Lin, Ke; Zhou, Yawen; Ai, Jingwen; Wang, Yan A.; Zhang, Senxin; Qiu, Chao; Lian, Chaoyang; Gao, Bo; Liu, Tingting; Wang, Hongyu; Zhang, Haocheng; Zhang, Yi; Fu, Zhangfan; Li, Dan; Jiang, Ning; Guo, Jingxin; Wu, Jing; Wang, Yan O.; Song, Shusen; Li, Qiang; Yin, Yanan; Xia, Jia; Xu, Yingjie; Yeap, Leng-Siew; Zheng, Xiaoqi; Gu, Ye; Liu, Hongyan; Zhang, Wenhong; Meng, Fei-Long
• Is Part Of: Emerging microbes & infections. Volume 11:Issue 1(2022)
• Page Start: 452
• Page End: 464
• Publication Date: 2022-12-31
• Subjects: SARS-CoV-2 -- COVID-19 -- B cell receptor -- inactivated vaccine -- antibody response -- class switch recombination; Medical microbiology -- Periodicals; Communicable diseases -- Periodicals; Infection -- Periodicals; 616.9041
• DOI: 10.1080/22221751.2022.2030197
• Languages: English
• ISSNs: 2222-1751

Abstract

ABSTRACT: Breakthrough infection of SARS-CoV-2 is a serious challenge, as increased infections were documented in fully-vaccinated individuals. Recipients with poor antibody response are highly vulnerable to reinfection, whereas those with strong antibody responses achieve sterilizing immunity. Thus far, biomarkers associated with levels of vaccine-elicited antibody response are still lacking. Here, we studied the antibody response of age- and gender-controlled healthy cohort, who received inactivated SARS-CoV-2 vaccines and profiled the B cell receptor repertoires in longitudinally consecutive samples. Upon vaccination, all vaccinated individuals displayed a convergent antibody response with shared common antibody clones and public neutralizing antibodies. Strikingly, poor vaccine-responders are distinguishable from strong vaccine-responders by a biased V-usage before vaccination and IgG to IgM mRNA ratio. These findings reveal molecular signatures associated with the different levels of vaccine-induced antibody response, which could be further developed into biomarkers for the design of vaccination strategies.